证券代码：301301 证券简称：川宁生物 公告编号：2024-025 伊犁川宁生物技术股份有限公司 关于质量回报双提升行动方案的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"或"川宁生物"）为践 行"要活跃资本市场、提振投资者信心"及"要大力提升上市公司质量和投资价 值，要采取更加有力有效措施，着力稳市场、稳信心"的指导思想，结合公司发 展战略、经营情况及财务状况，为维护广大投资者利益，增强投资者信心，进一 步提升公司质量和投资价值，公司于 2024 年 3 月 8 日制定了"质量回报双提升" 行动方案，现将相关进展情况公告如下： 一、聚焦主业，着力推动公司高质量发展 2024 年第一季度公司实现营业收入 15.23 亿元，同比增长 19.96%，2024 年 第一季度公司实现归属于上市公司股东净利润 3.53 亿元，同比增长 100.98%。 二、不断创新，提升公司核心竞争力 公司始终坚持以"科技创新"推动业务发展为核心思路，并将"研发创新" 确立为公司发展的核心驱动力，密切注视国际生物发酵、环保处 ...

伊犁川宁生物技术股份有限公司 独立董事 2023 年度述职报告 作为伊犁川宁生物技术股份有限公司（以下简称"公司"）的独立董事，2023 年度本人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《公司章 程》和《上市公司独立董事管理办法》等有关规定履行职责，本着恪尽职守、勤 勉尽责的工作态度积极出席相关会议，依法进行表决，有效促进了公司的规范运 作，充分发挥了独立董事的作用。现将 2023 年度履职情况报告如下： 一、个人基本情况及是否存在影响独立性的情况说明 （一）个人基本情况 1975 年出生，中国国籍，无境外永久居留权，中共党员，博士研究生学历， 近年来主持包括 4 项国家自然科学基金在内的省部级以上科研项目 10 余项，在 国际重要学术刊物发表多篇 SCI 论文，授权中国发明专利 16 件，获 2007 年、 2013 年新疆维吾尔自治区科技进步一等奖，2006 年、2010 年、2014 年、2016 年、2018 年新疆维吾尔自治区自然科学优秀论文奖，2019 年第九届新疆青年科 技奖。现任公司独立董事、新疆大学化学学院教授、博士生研究生导师。本人已 取得由深圳证券交易所颁发的独立董事资格 ...

股票代码：301301.SZ 环境、社会及 治理报告 20 2023 Environmental, Social and Governance Report 2023 Environmental, Social and Governance (ESG) Report 目录 CONTENTS | 前言 | | 全面管治 | | 绿色发展 | | 回馈社会 | | --- | --- | --- | --- | --- | --- | --- | | 关于本报告 | 03 | ESG管理 | 15 | 环境管理体系 | 47 | 社会责任 | | 董事长致辞 | 04 | 党政建设 | 16 | 碳管理 | 50 | 公益慈善 | | 关于川宁生物 | 05 | 公司治理 | 18 | 资源管理 | 51 | | | | | 商业道德 | 21 | 污染物防治 | 53 | | | | | | | 气候变化应对 | 55 | | | | | | 环境管理体系 | | --- | | 碳管理 | | 资源管理 | | 污染物防治 | | 气候变化应对 | 71 75 | | | 2 | | 4 | | 6 | | ...

长江证券承销保荐有限公司 关于伊犁川宁生物技术股份有限公司 2023年度内部控制自我评价报告的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"）作为伊犁川宁生物技术股 份有限公司（以下简称"川宁生物"或"公司"）首次公开发行股票并在创业板上市 的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》 及《企业内部控制基本规范》等相关规定，对《伊犁川宁生物技术股份有限公司2023 年度内部控制自我评价报告》（以下简称"《内部控制自我评价报告》"）进行了核 查，核查情况及意见如下： 一、公司内部控制评价情况 （一）内部控制评价范围 公司依据企业内部控制规范体系等相关法律、法规和规章制度的要求，并结合 公司相关制度、流程等规定，组织开展内部控制评价工作。公司按照风险导向原则 确定纳入评价范围的主要单位、业务和事项以及高风险领域。纳入内部控制评价范 围的单位资产总额合计占公司合并财务报表资产总额的95.99%，营业收入合计占公 司合并财务报表营业收入的99.05%；纳入评价范围的公司是伊犁川宁生物技术股份 有限公 ...

Financial Performance - The company's operating revenue for 2023 reached ¥4,823,335,006.68, representing a 26.24% increase compared to ¥3,820,657,857.71 in 2022[12]. - Net profit attributable to shareholders for 2023 was ¥940,563,998.57, a significant increase of 128.56% from ¥411,518,024.65 in 2022[12]. - The net cash flow from operating activities for 2023 was ¥1,292,388,960.85, up 86.86% from ¥691,638,049.25 in 2022[12]. - The total assets at the end of 2023 amounted to ¥10,138,649,127.55, a decrease of 2.42% from ¥10,390,399,359.24 at the end of 2022[12]. - The company's net assets attributable to shareholders increased by 12.18% to ¥6,960,483,793.26 at the end of 2023, compared to ¥6,204,485,260.20 at the end of 2022[12]. - The company reported a basic earnings per share of ¥0.42 for 2023, doubling from ¥0.21 in 2022[12]. - The company achieved a revenue of CNY 482,333.50 million in 2023, representing a year-on-year growth of 26.24%[55]. - The net profit attributable to the parent company reached CNY 94,056.40 million, marking a significant increase of 128.56% compared to the previous year[55]. - The basic earnings per share increased to CNY 0.42, reflecting a growth of 100.00% year-on-year[55]. Market and Industry Outlook - The company anticipates continued growth in the global antibiotic intermediate market, driven by increasing demand due to aging populations and rising disease incidence[19]. - The antibiotic intermediate market is expected to maintain a growth rate of over 4% in China, with a market size reaching ¥194.5 billion in 2022[19]. - The company is focusing on technological upgrades and innovation to enhance its competitive edge in the antibiotic intermediate market[20]. - The global synthetic biology market size reached $9.5 billion in 2021 and is projected to grow to approximately $15.1 billion in 2023, with forecasts of $19 billion in 2024 and $30.7 billion by 2026[25]. - The economic impact of synthetic biology is expected to reach between $1.8 trillion and $3.6 trillion annually between 2030 and 2040[25]. Research and Development - The company is positioned as a leading enterprise in the global biomanufacturing technology sector, leveraging regional resource advantages and years of R&D breakthroughs[27]. - The company focuses on the integration of R&D and production capabilities, which is crucial for maintaining competitive advantages in the synthetic biology market[27]. - The company has developed a complete synthetic biology technology platform, utilizing cutting-edge technologies for high-value natural products and biobased materials[32]. - The automated high-throughput platform can achieve DNA assembly capabilities of over 3,000 per month and genome editing capabilities of over 9,000 per month, significantly improving R&D efficiency[35]. - The company has established five categories of high-quality chassis strains, focusing on high-value natural health product raw materials and cosmetic raw materials[37]. - The company has a library of over 7 million independent IP enzymes and over 2,000 physical enzyme toolboxes, enhancing its product synthesis capabilities[37]. - The company is focused on expanding its product offerings and improving competitiveness through ongoing research and development initiatives[77]. - The company's R&D investment amounted to ¥55,258,054.34 in 2023, representing 1.15% of total revenue, an increase from 0.93% in 2022[79]. - The number of R&D personnel increased by 12.12% from 132 in 2022 to 148 in 2023, with a notable rise in the proportion of personnel holding undergraduate degrees[79]. Environmental Sustainability - The company has established a comprehensive environmental management system, including specific regulations and training programs to ensure effective environmental protection[191]. - The company received environmental impact assessment approvals for its projects, indicating compliance with regulatory requirements[193]. - The company has a valid pollution discharge permit effective from April 26, 2023, to April 25, 2028[194]. - The company has implemented measures to minimize negative environmental impacts, including the construction of waste treatment facilities[191]. - The company reported a total of 81.45 tons of sulfur dioxide emissions, which is below the regulatory limit[195]. - The company has successfully maintained its emissions within regulatory limits for various pollutants, including VOCs and nitrogen oxides[195]. - The total environmental protection investment by the company during the reporting period was CNY 557.94 million, with actual environmental protection tax paid amounting to CNY 1.1366 million[198]. - The company established an online monitoring system for environmental pollution, including real-time monitoring of wastewater and boiler flue gas emissions, with key indicators such as COD, ammonia nitrogen, and pH[197]. - The company implemented a carbon management system and established a carbon management leadership group to enhance its ability to control and manage carbon emissions, aligning with national carbon peak and carbon neutrality goals[198]. Corporate Governance - The company has established a comprehensive governance structure, including various specialized committees to ensure effective management and compliance[124]. - The company is committed to high-quality development and continuous innovation to enhance its core competitiveness[123]. - The company has received inquiries regarding its sales expectations and collaborations in strain development, reflecting investor interest in its growth prospects[121]. - The company held a total of 3 shareholder meetings during the reporting period, all conducted in compliance with relevant laws and regulations[125]. - The board of directors consists of 7 members, including 3 independent directors, and held 8 meetings during the reporting period, adhering to legal and procedural requirements[127]. - The company has a structured approach to salary determination, incorporating basic and performance-based salaries, which are adjusted according to regional salary levels and inflation[159]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 859.86 million[161]. - The highest remuneration was received by Zhao Hua, the Vice President and Chief Scientist, totaling CNY 187.68 million[161]. - The company has a dedicated internal audit department to oversee internal control and risk management processes[186]. Risk Management - The company is facing potential risks including industry policy changes, market risks, environmental risks, and R&D innovation risks[2]. - The company has implemented risk control measures, including a management system for foreign exchange hedging to comply with regulatory requirements[94]. - The company faces risks related to exchange rate fluctuations, internal control, performance, and legal compliance in its foreign exchange hedging activities[94]. - The company acknowledges potential risks from macroeconomic fluctuations and plans to implement strategies to minimize impacts on operations and financial performance[115]. - Key raw materials such as corn and soybean meal are subject to price volatility influenced by multiple factors, which could lead to a decline in gross margins if prices continue to rise or fluctuate abnormally[118]. Employee Management - The total number of employees at the end of the reporting period is 2,881, with 2,610 in the parent company and 271 in major subsidiaries[170]. - The professional composition includes 2,345 production personnel, 23 sales personnel, 350 technical personnel, 24 financial personnel, and 139 administrative personnel[170]. - The company has established a salary management system that combines fixed basic salary and variable salary to enhance employee motivation[171]. - The performance bonus system is designed to encourage employee engagement and improve management efficiency, following a three-level distribution system[171]. - The company has approved a stock incentive plan to motivate employees and align their interests with shareholders[181]. Investment and Financing - The total amount of funds raised by the company was RMB 111,400 million, with a net amount of RMB 102,168.31 million after deducting various fees[98]. - The company has committed RMB 20,000 million to the Shanghai Research Institute construction project, with 54.76% of the investment completed as of the reporting period[99]. - The company has also committed RMB 40,000 million to repay bank loans, which has been fully utilized[99]. - The total amount of over-raised funds was RMB 42,168.31 million, with RMB 20,000 million allocated to the green circular industrial park project and RMB 10,000 million to the Shanghai Research Institute project[101]. - The investment progress for the green circular industrial park project is currently at 92.69%, with an expected completion date of December 31, 2026[100].

伊犁川宁生物技术股份有限公司 关于召开公司2023年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《伊犁川宁生物技术股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，伊犁川宁生物技术股份有限公司（以 下简称"公司"）第二届董事会第五次会议审议通过了《关于召开公司 2023 年年 度股东大会的议案》，公司董事会决定于 2024 年 5 月 13 日（星期一）召开公司 2023 年年度股东大会。现就本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2023 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法性及合规性：本次股东大会召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 证券代码：301301 证券简称：川宁生物 公告编号：2024-019 4、会议召开的日期及时间： （1）现场会议召开时间：2024 年 5 月 13 日 15:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 ...

公司监事会对本公司 2023 年年度报告进行了认真严格的审核，出具如下书 面审核意见： 伊犁川宁生物技术股份有限公司监事会 关于公司第二届监事会第四次会议对相关事项的核查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《深圳证券 交易所上市公司规范运作指引》、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）等相关法律、法规、规范性文件及《伊犁川宁生物技术股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，伊犁川宁生物技术股份有 限公司（以下简称"公司"）监事会在审阅了相关会议资料并经讨论后，对相关 事项发表如下核查意见： 一、关于为公司董事、监事及高级管理人员投保责任保险的核查意见 经核查，我们一致认为：购买董监高责任险有利于完善公司风险管理体系， 保障公司董事、监事及高级管理人员充分履职，降低公司运营风险，审议程序合 法合规，不存在损害股东利益的情形。 二、关于公司 2023 年年度报告的核查意见 2、公司 2024 年第一季度报告的内容和格式符合中国证监会和深圳证券交 易所的各项规定，在所有重大方面按照企业会计准则的规定编制，公允反映了公 司 2024 年 3 月 31 日 ...

证券代码：301301 证券简称：川宁生物 公告编号：2024-015 伊犁川宁生物技术股份有限公司 关于2023年度计提资产减值准备的公告 公司及下属子公司对截至 2023 年 12 月 31 日存在可能发生减值迹象的资产 进行全面清查和资产减值测试后，2023 年度计提各类资产减值准备人民币 49,153,579.68 元，其中信用减值损失 6,502,796.67 元、资产减值损失 42,650,783.01 元。具体情况如下： （一）信用减值损失（损失以"-"号列示） 单位：元 | | 项 | 目 | 本期数 | | --- | --- | --- | --- | | 应收账款坏账损失 | | | -6,502,796.67 | | 合 计 | | | -6,502,796.67 | （二）资产减值损失（损失以"-"号列示） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 单位：元 一、本次计提资产减值准备情况概述 | | | 项 | 目 | 本期数 | | --- | --- | --- | --- | --- | | 存货跌价损失 | | | | ...

伊犁川宁生物技术股份有限公司 （一）对子公司、合营企业、联营企业、合作项目等的投资，包括但不限于下 列类型： 1、公司独立兴办的企业或独立出资的经营项目； 2、公司出资与其他境内（外）独立法人实体、自然人成立合资、合作公司或 开发项目； 第二条 本制度所称对外投资，是指公司为获取未来收益而将一定数量的货币 资金、股权、以及经评估后的实物或无形资产作价出资，对外进行各种形式的投资 活动。 第三条 按照投资期限的长短，公司对外投资分为短期投资和长期投资。 短期投资主要指公司购入的能随时变现且持有时间不超过一年（含一年）的投 资；长期投资主要指投资期限超过一年，不能随时变现或不准备变现的各种投资。 公司对外投资事项包括但不限于： 4、参股其他境内（外）独立法人实体； 5、经营资产出租、委托经营或与他人共同经营。 对外投资管理制度 第一章 总则 第一条 为规范公司对外投资行为，降低投资风险，提高投资收益，维护公司、 股东和债权人的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《深圳证券交易所创业板股票上市规则》及公司章程等规定，制定本制度。 - 1 - 符合公司发展战略；合理配置企业资源；促进要素 ...

伊犁川宁生物技术股份有限公司 2023 年度内部控制自我评价报告 伊犁川宁生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合伊犁川宁生物技术股份有限公司（以 下简称："本公司"或"公司"）内部控制制度和评价办法，在内部控制日常监督 和专项监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准 日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立 和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公司 董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记 载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营合法合规、资产安全、财务报告及相关 信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在固 有局限性，故仅能为实现上述目标提供合理保证。此外，由 ...